Stay updated with breaking news from Lipid Disorders. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The U.S. Food and Drug Administration recently approved a new indication for use for Wegovy (semaglutide) injection to reduce the risk of cardiovascular death, heart attack and stroke in adults with cardiovascular disease and either obesity or overweight.
The US Food and Drug Administration on March 8 approved drugmaker Novo Nordisk’s application to add cardiovascular benefits to the medicine’s label, making it the first weight-loss drug to also be cleared to reduce the risk of heart attack, stroke, or heart-related death in people at higher risk of these conditions.
The Centers for Medicare & Medicaid Services disclosed last week it will provide coverage for the popular weight loss drug Wegovy for patients at high risk for cardiovascular disease and stroke.
The injectable semaglutide from Novo Nordisk was shown to reduce risk of cardiovascular death, heart attack and stroke.
Wegovy, also chemically known as semaglutide, belongs to a class of drugs called GLP-1 agonists. Read more at straitstimes.com.